Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches
The development of novel tuberculosis (TB) multi-drug regimens that are more efficacious and of shorter duration requires a robust drug development pipeline. Advances in quantitative modeling and simulation can be used to maximize the utility of patient-level data from prior and contemporary clinica...
Main Authors: | Debra Hanna, Klaus Romero, Marco Schito |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971216311912 |
Similar Items
-
Tools to develop antibiotic combinations that target drug tolerance in Mycobacterium tuberculosis
by: Talia Greenstein, et al.
Published: (2023-01-01) -
Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
by: Jinwei Zhu, et al.
Published: (2023-09-01) -
Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling
by: Seung-Hyun Jeong, et al.
Published: (2022-12-01) -
Pharmacokinetic and pharmacodynamic integration and modeling of enrofloxacin in swine for Escherichia coli
by: Jianyi eWang, et al.
Published: (2016-02-01) -
Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Katharina Rox, et al.
Published: (2022-12-01)